Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases
| Autor: | Hendrick A. Marsman, Alexander M.M. Eggermont, Jan N. M. IJzermans, Joanne Verheij, Anne E. M. van der Pool, Fibo J. W. ten Kate, Cornelis Verhoef |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Liver injury
medicine.medical_specialty Chemotherapy Bevacizumab business.industry medicine.medical_treatment General Medicine medicine.disease Gastroenterology digestive system diseases Oxaliplatin Surgery Resection Oncology Internal medicine Monoclonal medicine business Neoadjuvant therapy medicine.drug Cohort study |
| Zdroj: | Journal of Surgical Oncology. 106:892-897 |
| ISSN: | 0022-4790 |
| DOI: | 10.1002/jso.23142 |
| Popis: | Background Chemotherapy (CTx) before resection of colorectal liver metastases (CRLM) may cause hepatic injury and postoperative complications. To ascertain whether adding bevacizumab, a monoclonal antibody against VEGF, to oxaliplatin-based CTx has an influence on liver injury and postoperative complications. Methods Patients with CRLM who received neoadjuvant CTx and underwent resection between 2003 and 2008 were analyzed whether or not they received bevacizumab added to oxaliplatin-based CTx. Results The total study group existed of 104 patients: 53 patients received oxaliplatin-based CTx and 51 patients received oxaliplatin-based CTx and bevacizumab. The overall complication rate (29%) was not significantly different between the two groups. The bevacizumab group exhibited less moderate sinusoidal dilatation (8% vs. 28%, P = 0.01). No difference in complication rate was found between patients given fewer than six cycles of oxaliplatin-based CTx and those given six or more cycles, or between patients with a short ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text